These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 27282640

  • 1. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X, Guo L, Zeng H, White SL, Furniss M, Balasubramanian B, Lis E, Lagrutta A, Sannajust F, Zhao LL, Xi B, Wang X, Davis M, Abassi YA.
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [Abstract] [Full Text] [Related]

  • 2. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A, Juhasz K, Thomas U, Stölzle-Feix S, Becker N, Dörr L, Beckler M, Bot C, George M, Fertig N.
    J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
    [Abstract] [Full Text] [Related]

  • 3. Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes.
    Bot CT, Juhasz K, Haeusermann F, Polonchuk L, Traebert M, Stoelzle-Feix S.
    J Pharmacol Toxicol Methods; 2018; 93():46-58. PubMed ID: 29940218
    [Abstract] [Full Text] [Related]

  • 4. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
    Qu Y, Vargas HM.
    Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
    [Abstract] [Full Text] [Related]

  • 5. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y, Honda Y, Watanabe H, Saiki S, Koyabu K, Itoh T, Nagasawa C, Nakamori C, Nakayama C, Iwasaki H, Suzuki S, Washio I, Takahashi E, Miyamoto K, Yamanishi A, Endo H, Shinozaki J, Nogawa H, Kunimatsu T.
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [Abstract] [Full Text] [Related]

  • 6. Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
    Huo J, Wei F, Cai C, Lyn-Cook B, Pang L.
    Toxicol Sci; 2019 Feb 01; 167(2):360-374. PubMed ID: 30247688
    [Abstract] [Full Text] [Related]

  • 7. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
    Nozaki Y, Honda Y, Tsujimoto S, Watanabe H, Kunimatsu T, Funabashi H.
    Toxicol Appl Pharmacol; 2014 Jul 01; 278(1):72-7. PubMed ID: 24742750
    [Abstract] [Full Text] [Related]

  • 8. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Patel D, Stohlman J, Dang Q, Strauss DG, Blinova K.
    Toxicol Sci; 2019 Jul 01; 170(1):167-179. PubMed ID: 30912807
    [Abstract] [Full Text] [Related]

  • 9. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T, Moriyama Y, Taniguchi T, Maeda S, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Miyamoto N.
    J Pharmacol Toxicol Methods; 2017 Jul 01; 85():73-81. PubMed ID: 28163191
    [Abstract] [Full Text] [Related]

  • 10. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
    Kitaguchi T, Moriyama Y, Taniguchi T, Ojima A, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Morita M, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Tanaka K, Washio I, Miyamoto N.
    J Pharmacol Toxicol Methods; 2016 Jul 01; 78():93-102. PubMed ID: 26657830
    [Abstract] [Full Text] [Related]

  • 11. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
    Goineau S, Castagné V.
    J Pharmacol Toxicol Methods; 2018 Jul 01; 90():58-66. PubMed ID: 29274391
    [Abstract] [Full Text] [Related]

  • 12. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
    Fermini B, Hancox JC, Abi-Gerges N, Bridgland-Taylor M, Chaudhary KW, Colatsky T, Correll K, Crumb W, Damiano B, Erdemli G, Gintant G, Imredy J, Koerner J, Kramer J, Levesque P, Li Z, Lindqvist A, Obejero-Paz CA, Rampe D, Sawada K, Strauss DG, Vandenberg JI.
    J Biomol Screen; 2016 Jan 01; 21(1):1-11. PubMed ID: 26170255
    [Abstract] [Full Text] [Related]

  • 13. Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging.
    Dempsey GT, Chaudhary KW, Atwater N, Nguyen C, Brown BS, McNeish JD, Cohen AE, Kralj JM.
    J Pharmacol Toxicol Methods; 2016 Jan 01; 81():240-50. PubMed ID: 27184445
    [Abstract] [Full Text] [Related]

  • 14. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM.
    J Pharmacol Toxicol Methods; 2013 Jan 01; 68(1):97-111. PubMed ID: 23702537
    [Abstract] [Full Text] [Related]

  • 15. Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay.
    da Rocha AM, Creech J, Thonn E, Mironov S, Herron TJ.
    Toxicol Sci; 2020 Feb 01; 173(2):402-415. PubMed ID: 31764978
    [Abstract] [Full Text] [Related]

  • 16. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes.
    Yamazaki D, Kitaguchi T, Ishimura M, Taniguchi T, Yamanishi A, Saji D, Takahashi E, Oguchi M, Moriyama Y, Maeda S, Miyamoto K, Morimura K, Ohnaka H, Tashibu H, Sekino Y, Miyamoto N, Kanda Y.
    J Pharmacol Sci; 2018 Apr 01; 136(4):249-256. PubMed ID: 29555184
    [Abstract] [Full Text] [Related]

  • 17. CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information.
    Nozaki Y, Honda Y, Watanabe H, Saiki S, Koyabu K, Itoh T, Nagasawa C, Nakamori C, Nakayama C, Iwasaki H, Suzuki S, Tanaka K, Takahashi E, Miyamoto K, Morimura K, Yamanishi A, Endo H, Shinozaki J, Nogawa H, Shinozawa T, Saito F, Kunimatsu T.
    Regul Toxicol Pharmacol; 2017 Aug 01; 88():238-251. PubMed ID: 28634147
    [Abstract] [Full Text] [Related]

  • 18. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K, Asakura K, Araki S, Ando H, Kazusa K, Kitaguchi T, Kunimatsu T, Suzuki S, Miyamoto N.
    J Pharmacol Toxicol Methods; 2017 Aug 01; 83():42-54. PubMed ID: 27646297
    [Abstract] [Full Text] [Related]

  • 19. Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment.
    Asahi Y, Nomura F, Abe Y, Doi M, Sakakura T, Takasuna K, Yasuda K.
    Eur J Pharmacol; 2019 Jan 05; 842():221-230. PubMed ID: 30391349
    [Abstract] [Full Text] [Related]

  • 20. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
    Colatsky T, Fermini B, Gintant G, Pierson JB, Sager P, Sekino Y, Strauss DG, Stockbridge N.
    J Pharmacol Toxicol Methods; 2016 Jan 05; 81():15-20. PubMed ID: 27282641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.